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Introduction
Dengue fever is caused by dengue viruses 
(DENV).  Transmission of  DENV 
has increased dramatically in the past 
two decades making DENV the most 
important human pathogens among 
arthropod-borne viruses (1). About 50-
100 million dengue fever infections occur 
every year in tropical and subtropical 
countries (2) – see Figure 1.
The emergence of  dengue 
haemorrhagic fever (DHF) in most 
tropical countries is a public health priority. 
Little is understood about dengue virus 
pathogenesis. No other animals develop 
symptoms and research has been limited 
to studies involving humans (1). 
DENV comprise four serotypes (DENV 1 to 4) 
but are epidemiologically similar (3). Dengue viruses are 
RNA viruses with a positive RNA strand, which belongs 
to the family Flaviviridae. There is a high mutation rate 
increasing biodiversity (4) and possibly increasing disease 
severity and problems with vaccination (4). 
History of dengue fever
The earliest record appears in a Chinese medical 
encyclopaedia (5). It may have spread via sailing ships, 
where mosquitoes used the stored water as a breeding site 
and could maintain the transmission cycle. 
The global epidemiology and transmission of  dengue 
viruses changed in Southeast Asia during World War 
II. Troop movement accelerated the spread of  viruses 
between populations and a few years later the first 
documented outbreaks of  DHF occurred in Manila, 
Philippines in 1953/54 (6).
The successful eradication of  Aedes aegypti in the 
Americas in 1970s reduced the spread of  dengue fever. 
After this programme was abandoned, A. aegypti re-
invaded most of  the countries causing a significant health 
problem (7). The true prevalence of  dengue fever in Africa 
is unclear because of  inadequate surveillance (2, 7).
Dengue viruses originated from an animal reservoir. 
Two distinct DENV transmission cycles are recognised 
(Figure 2):
• endemic/ epidemic cycle and
• sylvatic /zoonotic cycle.
Endemic and epidemic cycles involve the human host 
and viruses are transmitted by A. aegypti, A. albopictus and 
other mosquitoes as secondary vectors (3). The sylvatic 
transmission cycle involves monkeys and several different 
Aedes mosquitoes identified in Asia and West Africa (7).
transmission to humans
Transmission to humans is through the bite of  an infected 
mosquito, A. aegypti (Figure 3). This mosquito lays its eggs 
in containers found around the home (e.g. old car tyres, 
water storage containers). The adult mosquitoes feed on 
humans during daylight hours. There are two peaks of  
biting activity, early morning for 2 to 3 hours after daybreak 
and in the afternoon for several hours before dark. A. 
aegyptii females often feed on several persons during a 
single blood meal hence increasing the transmission rate 
(5). 
The incubation period is 3 - 14 days (average 4 to 7 
days). There follows an acute febrile period of  2 – 10 
days accompanied by nonspecific symptoms. During this 
period dengue viruses circulate in the peripheral blood. 
During this viraemic stage other biting mosquitoes 
become infected.
clinical picture
Dengue fever is mostly occurs in children and young 
adults (8). Clinical features vary with the age of  the patient 
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Figure 1. Dengue fever risk map 2008. (Source: WHO)
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although clinically occult infection occurs in about 80% 
(9). There are four presentations (Figure 3): 
• Non-specific febrile illness
• Classical dengue fever
• Dengue haemorrhagic fever 
• Dengue haemorrhagic fever with dengue shock 
syndrome, encephalopathy and  liver failure
Non-specific febrile illness: A maculo-papular 
rash occurs mostly in young children. Upper respiratory 
features, especially pharyngitis, are common (10). 
Classical dengue fever (DF) is primarily a disease 
of  older children and adults. It begins abruptly followed 
by three phases – febrile, critical and recovery (Figure 
4). The fever may be biphasic lasting 3 to 7 days and 
accompanied by a variety of  symptoms including severe 
headache, retro-orbital pain, fatigue,  nausea, vomiting, 
generalised  aches, arthralgia and myalgia, hence the term 
“break bone disease”(9). A flushed skin (face and neck) 
and maculo-papular rash are common (11). 
Haemorrhagic manifestations range from mild 
to severe; cutaneous petechiae and purpura, 
gum bleeding, epistaxis, gastrointestinal 
haemorrhage all can occur (5).
Recovery may be prolonged with 
weakness and depression (10). Laboratory 
findings include neutropaenia, lymphocytosis, 
thrombocytopaenia and elevated liver 
enzymes.  
Dengue haemorrhagic fever (DHF) 
is primarily a disease of  children under 
15 years in hyperendemic areas. It usually 
follows a secondary dengue infection and is 
characterized by high fever, haemorrhages, 
circulatory failure and hepatomegaly (11). Patients either 
recover or progress to the plasma leakage stage remaining 
ill despite normalisation of  temperature. Plasma leakage 
is characterized by tachycardia and hypotension with 
sweating, restlessness and cold extremities. Most patients 
recover, but in severe cases patients may develop circulatory 
shock (11). Mortality may reach 10 – 20% without early 
appropriate treatment but can be reduced to less than 1% 
with aggressive fluid replacement therapy.
Leucopaenia and thrombocytopaenia (less 
than100,000/mm3) are usually found between days 3 and 
8. Elevated liver enzymes are common.
Dengue shock syndrome (DSS) is associated with 
almost 50% mortality. Warning signs include sustained 
abdominal pain, vomiting, irritability or somnolence, a fall 
in body temperature and decrease in platelet count (10). 
Patients die from multi-organ failure and disseminated 
intravascular coagulation. DSS may be accompanied 
by encephalopathy caused by metabolic and electrolyte 
disturbances (11).
Haemostatic disturbances result from vascular 
changes, thrombocytopaenia and coagulation disorders 
arising from, for example,. a decreased fibrinogen level, 
and increased level of  fibrinogen degradation products 
(5). Other reported complications include liver failure, 
disseminated intravascular coagulation, myocarditis and 
acute renal failure.
pathogenesis
This is poorly understood. It is likely that viral, 
immunopathogenic and other host factors have a role. 
The main risk factors for severe disease include the 
virulence of  the strain of  the virus, previous infection 
with heterotypic DENV, age and genetic background of  
the person (12).
Figure 2. The two DENV transmission cycles. (Source: Nature reviews 
Microbiology 2007; 5: 518 – 528)
Figure 3. Dengue fever flow chart. (Source: WHO 1997 Dengue haemorrhagic fever: 
Diagnosis, Treatment, Prevention and Control, 2nd edition)
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The two main theories of  pathogenesis 
(5) are: 
1. The secondary-infection or 
immune enhancement hypothesis. This 
implies that patients having a second 
infection with heterologous virus serotype 
have a significantly higher chance of  
developing DHF and DSS (13). Pre-
existing antibodies cross-react with 
the virus and form antigen-antibody 
complexes, which then bind to the cell 
membrane of  leucocytes. Because the 
antibody is heterologous, the virus is not 
neutralised. This facilitates virus entry to 
cells resulting in higher viral titres (5, 13). 
Higher viral titres may result in an amplified 
cascade of  cytokines and complement 
activation causing endothelial dysfunction, 
platelets destruction and consumption 
of  coagulation factors leading to plasma leakage and 
haemorrhage (10).
2. The other hypothesis assumes that dengue viruses 
vary and some are associated with higher virulence, severe 
disease and have greater epidemic potential (14).
laboratory diagnosis
Laboratory diagnosis depends on virus isolation and 
identification of  virus-specific antibodies. Each method 
has its advantages and limitations and requires laboratories 
with the necessary infrastructure and technical expertise 
(15). Dengue viruses can be isolated from serum, plasma 
or leucocytes during the febrile phase of  the disease 
(within 6 days) and from post-mortem specimens of  liver, 
lung, spleen, lymph nodes, cerebrospinal fluid or pleural/
ascitic fluid. 
Serological diagnosis is more readily available. It is 
complicated by the existence of  cross-reactive antigenic 
determinants shared by all four dengue virus serotypes 
and members of  the flavivirus family (2). 
IgM antibodies are the first to appear and are detectable 
in 50% of  patients by days 3 – 5 after onset of  illness, 
increasing to 80% by day 5. IgG antibody is detectable at 
low titres at the end of  first week, increasing thereafter 
and still detectable after several months. During secondary 
dengue infection antibody titres rise rapidly and react 
broadly against many flaviviruses (15). 
Molecular methods (nucleic acid detection assays) may 
identify virus within 24 – 48 hours, but these methods are 
expensive and require experienced personnel.
Management of dengue infections
There is no specific therapy. Uncomplicated dengue 
infection usually resolves spontaneously. Patients with 
life threatening complications should be managed in 
hospital with supportive treatment. Fluid replacement 
and close monitoring of  fluid and electrolytes balance are 
vital. Isotonic solutions (e.g. 0.9% saline, Ringer’s lactate 
or Hartmann’s solution) should be used (15). Signs of  
successful therapy are: 
• Improving central and peripheral circulation 
(decreasing tachycardia, increasing blood pressure, 
capillary refill time < 2 seconds) and
• Improving end-organ perfusion e.g. stable 
conscious level, urine output >=0.5 ml/kg/hour, 
degreasing metabolic acidosis (15). 
Give paracetamol for fever and analgesia.  Avoid aspirin, 
ibuprofen and other non-steroidal anti-inflammatory 
agents as they may aggravate gastritis or bleeding (15). 
Acetylsalicylic acid (aspirin) may be associated with Reye’s 
syndrome.
Monitor patients at least 6 hourly in 24 hours 
and particularly around the time of  defervescence of  
symptoms as shock may develop.  The indications for 
hospitalisation are:
• Poor oral intake
• Bleeding
• Change in level of  consciousness
• Laboratory evidence of  DHF 
• Pregnancy, infancy, old age, obesity and diabetes     
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Figure 4. Phases of  infection resulting in dengue haemmorhagic fever. (Source: Centers for 
Disease Control and Prevention, Atlanta, USA)
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Impact of global changes to the spread of 
dengue viruses.
Several factors contribute to the increase of  dengue 
viruses (Figure 5): 
• Increasing human population and urbanisation 
were critical factors in the past enabling the spread of  
viruses. The dengue virus broke free of  its sylvatic cycle 
and established itself  as the endemic human disease we 
see today (7).
• Increased urbanisation. The industrialisation 
and urbanisation are creating large populations of  
susceptible hosts and fertile habitats for mosquito 
vectors. 
• Poverty associated with rapid population growth 
leads to concentration of  people without the necessary 
infrastructure for the safe storage and distribution of  
water and drainage. Used containers and tyres provide 
breeding sites for mosquito vectors.  
• Decreased vector control in areas where dengue 
is epidemic.
• Human travel and particularly air travel.
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Figure 5. Average annual number of  DF/DHF cases. (Source: 
WHO -http://www.who.int/csr/disease/dengue/impact/en/)
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